©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Non-selective beta-blockers in cirrhosis: Current concepts and controversies
Neil Rajoriya, Dhiraj Tripathi, Department of Hepatology, the New Queen Elizabeth Hospital, Birmingham B15 2TH, United Kingdom
Author contributions: All the authors contributed equally to this manuscript.
Conflict-of-interest statement: Authors declare no conflict of interests for this article.
Correspondence to: Dr. Dhiraj Tripathi, Consultant Hepatologist, Honorary Senior Lecturer, Department of Hepatology, the New Queen Elizabeth Hospital, Edgbaston, Queen Elizabeth Medical Centre, Birmingham B15 2TH, United Kingdom. dhiraj.tripathi@uhb.nhs.uk
Telephone: +44-121-3714672 Fax: +44-121-6272449
Received: August 28, 2015
Peer-review started: September 1, 2015
First decision: November 24, 2015
Revised: December 11, 2015
Accepted: January 5, 2016
Article in press: January 7, 2016
Published online: March 9, 2016
Processing time: 189 Days and 11 Hours
Peer-review started: September 1, 2015
First decision: November 24, 2015
Revised: December 11, 2015
Accepted: January 5, 2016
Article in press: January 7, 2016
Published online: March 9, 2016
Processing time: 189 Days and 11 Hours
Core Tip
Core tip: This article serves to discuss the changing role of non-selective beta-blockers in liver disease and portal hypertension. For many years non-selective beta-blockers have been at the forefront in reducing portal hypertensive complications such as variceal haemorrhage, however recent data has questioned their role in advanced liver disease. This article reviews their role in portal hypertension, discusses recent advances in the field and reviews the controversy recently generated regarding their role in advanced liver disease.